Involvement of the TGF-β and β-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1317-1330

  Noordhuis, Maartje G ^a   Fehrmann, Rudolf S N ^a   Wisman, G Bea A ^a   Nijhuis, Esther R ^a   Van Zanden, Jelmer J ^a   Moerland, Perry D ^b,c   Ver Loren Van Themaat, Emiel ^b   Volders, Haukeline H ^a   Kok, Mirjam ^a   Ten Hoor, Klaske A ^a   Hollema, Harry ^a   De Vries, Elisabeth G E ^a   De Bock, Geertruida H ^a   Van Der Zee, Ate G J ^a   Schuuring, Ed ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NETHERLANDS BIOINFORMATICS CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BETA CATENIN; GLYCOSPHINGOLIPID; PROTEIN BAD; PROTEIN P120; PROTEINASE ACTIVATED RECEPTOR 1; SMAD4 PROTEIN; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CTNNAL1 GENE; CTNND1 GENE; DKK3 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK FACTOR; SIGNAL TRANSDUCTION; TCF4 GENE; UTERINE CERVIX CANCER; WNT5A GENE;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CATENINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA; UTERINE CERVICAL NEOPLASMS;

EID: 79952725039     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2320     Document Type: Article

References (50)

1. Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer?Gynecol Oncol 2004;92:525-9.
2. Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol 2007;12:165-75. (Pubitemid 46944641)
3. Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:535-40. (Pubitemid 27348428)
4. Sevin BU, Nadji M, Lampe B, Lu Y, Hilsenbeck S, Koechli OR, et al. Prognostic factors of early stage cervical cancer treated by radical hysterectomy. Cancer 1995;76:1978-86.
5. van de Putte G, Holm R, Lie AK, Trope CG, Kristensen GB. Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol 2003;89:140-7. (Pubitemid 36406387)
6. Lee IJ, Park KR, Lee KK, Song JS, Lee KG, Lee JY, et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2002;54:768-79.
7. Gortzak-Uzan L, Jimenez W, Nofech-Mozes S, Ismiil N, Khalifa MA, Dubé V, et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard?Gynecol Oncol 2010;116:28-32.
8. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
9. Molloy T, van't Veer LJ. Recent advances in metastasis research. Curr Opin Genet Dev 2008;18:35-41.
10. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
11. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
12. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005;37:182-6.
13. Kwon HC, Kim SH, Roh MS, Kim JS, Lee HS, Choi HJ, et al. Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 2004;47:141-52.
14. Biewenga P, Buist MR, Moerland PD, Ver Loren van Themaat E, van Kampen AH, ten Kate FJ, et al. Gene expression in early stage cervical cancer. Gynecol Oncol 2008;108:520-6.
15. Lyng H, Brvig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006;7:268.
16. Grigsby PW, Watson M, Powell MA, Zhang Z, Rader JS. Gene expression patterns in advanced human cervical cancer. Int J Gynecol Cancer 2006;16:562-7.
17. Kim TJ, Choi JJ, Kim WY, Choi CH, Lee JW, Bae DS, et al. Gene expression profiling for the prediction of lymph node metastasis in patients with cervical cancer. Cancer Sci 2008;99:31-8. (Pubitemid 350239028)
18. Draghici S, Khatri P, Eklund AC, Szallasi Z. Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 2006;22:101-9. (Pubitemid 43152029)
19. Jarvinen AK, Hautaniemi S, Edgren H, Auvinen P, Saarela J, Kallioniemi OP, et al. Are data from different gene expression microarray platforms comparable?Genomics 2004;83:1164-8.
20. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14. (Pubitemid 38525286)
21. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008;36:D480-4.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
23. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
24. Crijns AP, Fehrmann RS, de JS, Gerbens F, Meersma GJ, Klip HG, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med 2009;6:e24.
25. Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, et al. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome. J Clin Oncol 2009;27:2209-16.
26. Sherlock G. Analysis of large-scale gene expression data. Brief Bioinform 2001;2:350-62.
27. Alter O, Brown PO, Botstein D. Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A 2000;97:10101-6.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289-300.
29. Noordhuis MG, Eijsink JJ, ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo) radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-97.
30. Kloth JN, Kenter GG, Spijker HS, Uljee S, Corver WE, Jordanova ES, et al. Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod Pathol 2008;21:866-75. (Pubitemid 351896661)
31. Van de Putte G, Kristensen GB, Baekelandt M, Lie AK, Holm R. E-cadherin and catenins in early squamous cervical carcinoma. Gynecol Oncol 2004;94:521-7. (Pubitemid 39028907)
32. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR, et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008;133:66-77. (Pubitemid 351442989)
33. Yanagisawa M, Huveldt D, Kreinest P, Lohse CM, Cheville JC, Parker AS, et al. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. J Biol Chem 2008;283:18344-54.
34. Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, et al. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone. Oncogene 2009;28:1005-15.
35. Wheelock MJ, Johnson KR. Cadherin-mediated cellular signaling. Curr Opin Cell Biol 2003;15:509-14. (Pubitemid 37176958)
36. Elliott RL, Blobe GC. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005;23:2078-93. (Pubitemid 46211385)
37. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25:435-57. (Pubitemid 44922360)
38. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004;303:1483-7. (Pubitemid 38314410)
39. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, Ten Kate FJ, Reitsma PH, et al. Analysis of gene expression identifies differentially expressed genes and pathways associated with lymphatic dissemination in patients with adenocarcinoma of the esophagus. Ann Surg Oncol 2008;15:3459-70.
40. Imura J, Ichikawa K, Takeda J, Fujimori T. Beta-catenin expression as a prognostic indicator in cervical adenocarcinoma. Int J Mol Med 2001;8:353-8.
41. Reynolds AB, Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 2004;23:7947-56. (Pubitemid 39468853)
42. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006;6:1-14.
43. Zhao S, Venkatasubbarao K, Lazor JW, Sperry J, Jin C, Cao L, et al. Inhibition of STAT3 Tyr705 phosphorylation by Smad4 suppresses transforming growth factor beta-mediated invasion and metastasis in pancreatic cancer cells. Cancer Res 2008;68:4221-8.
44. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-6. (Pubitemid 37487967)
45. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res 2006;66:9583-90.
46. Eger A, Stockinger A, Park J, Langkopf E, Mikula M, Gotzmann J, et al. Beta-catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition. Oncogene 2004;23:2672-80. (Pubitemid 38586321)
47. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601. (Pubitemid 351627379)
48. Hu X, Schwarz JK, Lewis JS Jr., Huettner PC, Rader JS, Deasy JO, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010;70:1441-8.
49. Dihlmann S, von Knebel DM. Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer 2005;113:515-24. (Pubitemid 40038726)
50. Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19:77-91.